JAMA publishes inaccurate study on data breaches

While there have been numerous data breaches in the past few years, it seems a research letter on the topic published in the Journal of the American Medical Association in April overstated the problem.

JAMA’s correction notice acknowledged five mistakes in the text and a dozen in a data table, but the authors said none of them affected the study's conclusions. Retraction Watch, a blog devoted to such retractions, called the situation a "mega-correction" because one result changed from statistically significant to “borderline significant” after the revision.

Lead author Vincent Liu, MD, MS, research scientist at the Kaiser Permanente Northern California Division of Research, told Retraction Watch that JAMA inadvertently published the table with outdated information. “Once we became aware that the older version was published, we corrected the table with the editorial staff. The overall study findings remained consistent,” according to the blog post.

The research letter was a review of 949 breaches of protected health information, as defined by HIPAA, between 2010 and 2013. The breaches affected the records of 29 million patients, not the 29.1 million originally mentioned in the original study published in April.

Read the original study.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.